Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
Abstract: A pharmaceutical composition comprising an antibody drug conjugate comprising an antibody or antigen binding fragment thereof that binds to 191P4D12 conjugated to one or more units of monomethyl auristatin E (MMAE) and a pharmaceutically acceptable excipient comprising L-histidine, polysorbate-20 (TWEEN-20), and at least one of trehalose dihydrate and sucrose.
Type:
Application
Filed:
October 15, 2019
Publication date:
June 9, 2022
Applicants:
AGENSYS, INC., SEAGEN INC.
Inventors:
Orla MCGARVEY, Gayathri RATNASWAMY, Yingqing SUN, Marie Rose VAN SCHRAVENDIJK
Abstract: The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.
Type:
Application
Filed:
February 28, 2018
Publication date:
June 9, 2022
Applicant:
SEAGEN INC.
Inventors:
Andrew WAIGHT, Chris LEISKE, Travis BIECHELE, Django SUSSMAN, Patrick BURKE, Jocelyn LEISKE
Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
Type:
Grant
Filed:
June 30, 2016
Date of Patent:
June 7, 2022
Assignee:
Seagen Inc.
Inventors:
Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
Abstract: The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.
Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
Type:
Application
Filed:
October 20, 2021
Publication date:
May 5, 2022
Applicant:
Seagen Inc.
Inventors:
Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.
Type:
Application
Filed:
May 26, 2021
Publication date:
February 24, 2022
Applicant:
Seagen Inc.
Inventors:
Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.
Type:
Grant
Filed:
March 2, 2018
Date of Patent:
February 22, 2022
Assignee:
Seagen Inc.
Inventors:
Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
Type:
Application
Filed:
June 25, 2021
Publication date:
January 27, 2022
Applicant:
SEAGEN INC.
Inventors:
Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
Abstract: Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
Abstract: The invention provides bivalent antibodies including two light and heavy chain pairs. The N-termini of one or both light and heavy chain pairs are linked via linkers comprising a protease cleavage site to coiled-coil forming peptides that associate to form a coiled coil reducing binding affinity of at least one light-heavy chain pair to a target.
Type:
Grant
Filed:
December 8, 2017
Date of Patent:
January 25, 2022
Assignee:
SEAGEN INC.
Inventors:
Vivian Trang, Matthew R. Levengood, Peter Senter
Abstract: In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.
Abstract: This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.
Type:
Grant
Filed:
June 8, 2017
Date of Patent:
December 7, 2021
Assignee:
Seagen Inc.
Inventors:
William Arthur, Travis Biechele, Rory Rohm, Robert Thurman
Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
Type:
Grant
Filed:
January 4, 2018
Date of Patent:
March 8, 2022
Assignee:
SEAGEN INC.
Inventors:
Maria Leia Smith, Django Sussman, William Arthur, Albina Nesterova